Frontiers in endocrinology · 2022
Case report: Two sisters with a germline CHEK2 variant and distinct endocrine neoplasias.
Клинический случайПоддержка исследования: вне правительства СШАПоддержка NIH: внешняя программаСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Vallera Raphaelle D, Ding Yanli, Hatanpaa Kimmo J, Bishop Justin A, Mirfakhraee Sasan, Alli Abdel A, Tevosian Sergei G, Tabebi Mouna, Gimm Oliver, Söderkvist Peter, Estrada-Zuniga Cynthia, Dahia Patricia L M, Ghayee Hans K
Аннотация
Genetic testing has become the standard of care for many disease states. As a result, physicians treating patients who have tumors often rely on germline genetic testing results for making clinical decisions. Cases of two sisters carrying a germline CHEK2 variant are highlighted whereby possible other genetic drivers were discovered on tumor analysis. CHEK2 (also referred to as CHK2) loss of function has been firmly associated with breast cancer development. In this case report, two siblings with a germline CHEK2 mutation also had distinct endocrine tumors. Pituitary adenoma and pancreatic neuroendocrine tumor (PNET) was found in the first sibling and pheochromocytoma (PCC) discovered in the second sibling. Although pituitary adenomas, PNETs, and PCC have been associated with NF1 gene mutations, the second sister with a PCC did have proven germline CHEK2 with a pathogenic somatic NF1 mutation. We highlight the clinical point that unless the tumor is sequenced, the real driver mutation that is causing the patient's tumor may remain unknown.